$KZR
Kezar Life Sciences, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022016897 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.067M $4.977M $4.934M
YoY Change 27.57% 35.69% 31.22%
% of Gross Profit
Research & Development $13.86M $11.35M $10.94M
YoY Change 31.66% 21.46% 17.85%
% of Gross Profit
Depreciation & Amortization $300.0K $200.0K $417.0K
YoY Change -20.63% -33.33% 12.1%
% of Gross Profit
Operating Expenses $18.93M $16.32M $15.88M
YoY Change 30.54% 25.47% 21.69%
Operating Profit -$18.93M -$16.32M -$15.88M
YoY Change 30.54% 25.47% 21.69%
Interest Expense $310.0K $272.0K $254.0K
YoY Change 737.84% 370.37%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$17.85M -$16.19M -$16.02M
YoY Change 23.41% 24.88% 23.36%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$17.85M -$16.19M -$16.02M
YoY Change 23.41% 24.88% 23.32%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25 -$0.25 -$0.26
Diluted Earnings Per Share -$0.25 -$0.25 -$264.3K
COMMON SHARES
Basic Shares Outstanding 68.37M 64.28M 56.71M
Diluted Shares Outstanding 72.15M 64.28M 60.63M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $290.4M $306.8M $242.6M
YoY Change 140.46% 137.91% 70.49%
Cash & Equivalents $64.45M $105.4M $38.91M
Short-Term Investments $225.9M $201.5M $203.7M
Other Short-Term Assets $818.0K $685.0K $1.056M
YoY Change -79.52% -84.33% -68.94%
Inventory
Prepaid Expenses $7.726M $3.805M $2.331M
Receivables
Other Receivables
Total Short-Term Assets $298.9M $311.3M $246.0M
YoY Change 139.62% 133.47% 68.84%
LONG-TERM ASSETS
Property, Plant & Equipment $3.369M $3.518M $3.041M
YoY Change -42.45% 16.61% -5.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $282.0K $282.0K $282.0K
YoY Change 0.0% 0.0% -6.0%
Total Long-Term Assets $5.843M $6.174M $5.870M
YoY Change -4.78% -2.4% -11.06%
TOTAL ASSETS
Total Short-Term Assets $298.9M $311.3M $246.0M
Total Long-Term Assets $5.843M $6.174M $5.870M
Total Assets $304.8M $317.5M $251.9M
YoY Change 132.85% 127.32% 65.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.274M $1.922M $1.359M
YoY Change 47.38% 17.7% -62.25%
Accrued Expenses $5.992M $4.646M $4.378M
YoY Change -5.32% 45.83% 51.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.595M $7.853M $6.978M
YoY Change 21.89% 32.12% -8.18%
LONG-TERM LIABILITIES
Long-Term Debt $9.780M $9.728M $9.675M
YoY Change
Other Long-Term Liabilities $2.207M $2.557M $2.898M
YoY Change -37.58% -33.45% -29.32%
Total Long-Term Liabilities $9.780M $9.728M $9.675M
YoY Change 176.58% 153.2% 135.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.595M $7.853M $6.978M
Total Long-Term Liabilities $9.780M $9.728M $9.675M
Total Liabilities $21.58M $20.14M $19.55M
YoY Change 89.18% 105.78% 67.1%
SHAREHOLDERS EQUITY
Retained Earnings -$230.7M -$212.9M -$196.7M
YoY Change 38.64% 40.07% 41.51%
Common Stock $515.4M $511.4M $429.8M
YoY Change 80.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $283.2M $297.4M $232.3M
YoY Change
Total Liabilities & Shareholders Equity $304.8M $317.5M $251.9M
YoY Change 132.85% 127.32% 65.37%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$17.85M -$16.19M -$16.02M
YoY Change 23.41% 24.88% 23.32%
Depreciation, Depletion And Amortization $300.0K $200.0K $417.0K
YoY Change -20.63% -33.33% 12.1%
Cash From Operating Activities -$16.36M -$13.29M -$13.31M
YoY Change 64.36% 1.89% 59.32%
INVESTING ACTIVITIES
Capital Expenditures -$603.0K -$182.0K $450.0K
YoY Change 2219.23% 658.33%
Acquisitions
YoY Change
Other Investing Activities -$24.10M $1.692M -$59.08M
YoY Change -162.59% -89.6% 8462.75%
Cash From Investing Activities -$24.71M $1.510M -$59.53M
YoY Change -164.2% -90.71% 8565.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 185.0K 78.32M 48.85M
YoY Change -91.64% 28175.09% 355.03%
NET CHANGE
Cash From Operating Activities -16.36M -13.29M -13.31M
Cash From Investing Activities -24.71M 1.510M -59.53M
Cash From Financing Activities 185.0K 78.32M 48.85M
Net Change In Cash -40.88M 66.54M -23.97M
YoY Change -232.99% 1807.77% -1527.02%
FREE CASH FLOW
Cash From Operating Activities -$16.36M -$13.29M -$13.31M
Capital Expenditures -$603.0K -$182.0K $450.0K
Free Cash Flow -$15.76M -$13.11M -$13.76M
YoY Change 58.71% 0.68% 64.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001645666
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38542
dei Entity Registrant Name
EntityRegistrantName
Kezar Life Sciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3366145
dei City Area Code
CityAreaCode
650
us-gaap Operating Lease Payments
OperatingLeasePayments
580000
dei Entity Address Address Line1
EntityAddressAddressLine1
4000 Shoreline Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2022Q2 us-gaap Assets Current
AssetsCurrent
311328000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
211654000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3518000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3283000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2374000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2714000
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
dei Local Phone Number
LocalPhoneNumber
822-5600
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
KZR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68369530
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105387000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62882000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
201451000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
145473000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3805000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2570000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
685000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
729000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
282000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
282000
CY2022Q2 us-gaap Assets
Assets
317502000
CY2021Q4 us-gaap Assets
Assets
217933000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1922000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2028000
CY2022Q2 kzr Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4646000
CY2021Q4 kzr Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4985000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1285000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1199000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7853000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8212000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2557000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3223000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9728000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9622000
CY2022Q2 us-gaap Liabilities
Liabilities
20138000
CY2021Q4 us-gaap Liabilities
Liabilities
21057000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68341642
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68341642
us-gaap Interest Expense
InterestExpense
526000
us-gaap Interest Expense
InterestExpense
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56259747
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56259747
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
68000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
56000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
511325000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
377765000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1164000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-291000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212865000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180654000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
297364000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
196876000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
317502000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
217933000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11346000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9341000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22290000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18627000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4977000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3668000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9911000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7430000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
16323000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
13009000
us-gaap Operating Expenses
OperatingExpenses
32201000
us-gaap Operating Expenses
OperatingExpenses
26057000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16323000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13009000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32201000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26057000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
408000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
47000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
516000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
101000
CY2022Q2 us-gaap Interest Expense
InterestExpense
272000
CY2021Q2 us-gaap Interest Expense
InterestExpense
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16187000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12962000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16187000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
297364000
us-gaap Net Income Loss
NetIncomeLoss
-32211000
us-gaap Net Income Loss
NetIncomeLoss
-25956000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64279634
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64279634
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51904701
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51904701
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62465092
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62465092
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51483709
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51483709
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16187000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12962000
us-gaap Net Income Loss
NetIncomeLoss
-32211000
us-gaap Net Income Loss
NetIncomeLoss
-25956000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-64000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-13000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-39000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-24000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-318000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-834000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-382000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-15000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-873000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-18000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16569000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12977000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33084000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25974000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
196876000
CY2022Q1 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
208000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3104000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-491000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16024000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
232315000
CY2022Q2 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
420000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3298000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-382000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
140978000
CY2021Q1 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
48000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5154000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62882000
CY2021Q1 kzr Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises
7000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1928000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12994000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
140637000
CY2021Q2 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
282000
CY2021Q2 kzr Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises
7000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1937000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-15000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12962000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
129886000
us-gaap Profit Loss
ProfitLoss
-32211000
us-gaap Profit Loss
ProfitLoss
-25956000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
848000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
745000
us-gaap Share Based Compensation
ShareBasedCompensation
6402000
us-gaap Share Based Compensation
ShareBasedCompensation
3865000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-579000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1045000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
106000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-4000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1191000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
21000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-560000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-576000
us-gaap Operating Lease Payments
OperatingLeasePayments
580000
us-gaap Operating Lease Payments
OperatingLeasePayments
504000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26603000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21402000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
632000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
142080000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
37913000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
84689000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
53500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58023000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15563000
kzr Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
126542000
kzr Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
10673000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
628000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
344000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
127170000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11017000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-39000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-24000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42505000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3283000
CY2022Q2 us-gaap Depreciation
Depreciation
200000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21228000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105387000
us-gaap Depreciation
Depreciation
500000
CY2021Q2 us-gaap Depreciation
Depreciation
300000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
275000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26382000
kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
0
kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
14000
kzr Unpaid Offering Costs In Accrued Liabilities
UnpaidOfferingCostsInAccruedLiabilities
0
kzr Unpaid Offering Costs In Accrued Liabilities
UnpaidOfferingCostsInAccruedLiabilities
25000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
557000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16000
us-gaap Interest Paid Net
InterestPaidNet
219000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212900000
us-gaap Depreciation
Depreciation
500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions include the stock-based compensation, and accrued research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company anticipates that the ongoing COVID-19 pandemic, recent geopolitical events and supply-chain concerns could have an impact on our clinical development timelines. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s consolidated financial statements.</span></p>
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6945184
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.95
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
194700000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
937000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
112520000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
108000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
305244000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
304315000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
305244000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
304315000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7657000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6935000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4139000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3652000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3518000
CY2022Q2 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
1434000
CY2021Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
1642000
CY2022Q2 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
1180000
CY2021Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
1043000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1697000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1970000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
236000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
231000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
99000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
99000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4646000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4985000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
298000
us-gaap Operating Lease Cost
OperatingLeaseCost
550000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
190000
us-gaap Variable Lease Cost
VariableLeaseCost
301000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
799000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1635000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1684000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
282000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4400000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
558000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3842000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1285000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2557000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3842000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
386000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
431000
CY2022Q2 kzr Cumulative Accretion Of Final Fee
CumulativeAccretionOfFinalFee
114000
CY2021Q4 kzr Cumulative Accretion Of Final Fee
CumulativeAccretionOfFinalFee
53000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9728000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9622000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
5217000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
4783000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
10000000
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P20Y
CY2022Q2 kzr Maximum Ownership Percentage Of Holders Upon Exercise Of Warrants
MaximumOwnershipPercentageOfHoldersUponExerciseOfWarrants
0.0499
CY2022Q2 kzr Maximum Ownership Percentage Allowed To Be Increased Or Decreased By Warrant Holders Upon Prior Notice
MaximumOwnershipPercentageAllowedToBeIncreasedOrDecreasedByWarrantHoldersUponPriorNotice
0.1999
CY2022Q2 kzr Class Of Warrants Or Rights Exercised
ClassOfWarrantsOrRightsExercised
0
CY2020Q1 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2020-02-04
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2020Q1 kzr Class Of Warrant Or Rights Expiration Date
ClassOfWarrantOrRightsExpirationDate
2040-02-04
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2884615
CY2020Q2 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2020-06-11
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2020Q2 kzr Class Of Warrant Or Rights Expiration Date
ClassOfWarrantOrRightsExpirationDate
2040-06-11
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
909091
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3793706
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
77363000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2448635
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.73
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
125361
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1191000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
62131
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.48
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9206327
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23277000
CY2022Q2 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
4221972
CY2022Q2 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
6.38
kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P6Y9M18D
CY2022Q2 kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue
14989000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.032
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.005
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3298000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1937000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6402000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3865000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.843
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.884
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.871
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.877
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.843
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.884
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.871
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.881
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.028
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.032
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.010
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q4 kzr Research And Development Tax Credit Maximum Utilization Against Employers Portion Of Payroll Tax
ResearchAndDevelopmentTaxCreditMaximumUtilizationAgainstEmployersPortionOfPayrollTax
250000
kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
79000
kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
154000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16187000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12962000
us-gaap Net Income Loss
NetIncomeLoss
-32211000
us-gaap Net Income Loss
NetIncomeLoss
-25956000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64279634
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51904701
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62465092
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51483709
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9248262
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9248262
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7314814
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7314814

Files In Submission

Name View Source Status
0000950170-22-016897-index-headers.html Edgar Link pending
0000950170-22-016897-index.html Edgar Link pending
0000950170-22-016897.txt Edgar Link pending
0000950170-22-016897-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img38312587_0.jpg Edgar Link pending
kzr-20220630.htm Edgar Link pending
kzr-20220630.xsd Edgar Link pending
kzr-ex10_1.htm Edgar Link pending
kzr-ex10_2.htm Edgar Link pending
kzr-20220630_cal.xml Edgar Link unprocessable
kzr-20220630_def.xml Edgar Link unprocessable
kzr-20220630_pre.xml Edgar Link unprocessable
kzr-20220630_lab.xml Edgar Link unprocessable
kzr-20220630_htm.xml Edgar Link completed
kzr-ex31_1.htm Edgar Link pending
kzr-ex31_2.htm Edgar Link pending
kzr-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable